A subcommittee which would draft a mechanism to sale prescription drugs online says studying other countries online drug sales should also be involved in the part of the regulations for the same. The committee was formed by the Drugs Controller General of India (DCGI). Dr Harshdeep Kamble, Maharashtra Food & Drugs Administration Commissioner will lead the first meeting of the sub-committee which was planned in 2nd week of August.
Raghurama Bhandary, Karnataka drugs controller, the drugs controller from Delhi, Odhisha and Dr S Eswara Reddy, the joint drugs controller of the Central Drugs Standard Control Organization (CDSCO) are the other members of the committee. The online pharmacy topic was the top discussion in the 48th Drugs Consultative Committee (DCC) meeting concluded recently as the growing population of patients looking for easy and efficient access to drugs on time. A licensed retailer can only sale drugs on the prescription of the doctor as per the rules stated in Section 18 (c) of Drugs and Cosmetics Act, 1940 to be read with Rule 65. A senior official said, “The safety of the patients will not be compromised and it is not acceptable to sell through online distribution without legal approval”.
Other News
India Medical Device Pricing Strategy: Ensuring Growth & Affordability
India’s National Pharmaceutical Pricing Authority (NPPA) is developing a specialized India medical device pricing strategy for medical devices, transitioning away from the conventional drug-centric framework. This innovative strategy will incorporate international pricing tactics tailored to […]
Read MoreImports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read MoreErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read MoreTUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More